•  
  •  
  •  
  •  

2026-07-25 06:28:12

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%

Keywords Selected:  Biotech

IPO News

  • Concord Biotech Limited's IPO to open on Friday, 4th August, 2023, sets price band at ₹705 to ₹741 per Equity Share
  • Windlas Biotech Ltd posts consolidated PAT of Rs. 11.44 crores in Q4FY23
  • Ahmedabad-based Concord Biotech gets SEBI nod for IPO
  • Rare Enterprises and Quadria Capital-backed Concord Biotech files DRHP for IPO

Stock Report

  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million
  • Vivo Bio Tech Limited Announces Q1 FY27 Results; Net Profit Rebounds Sequentially to ₹18.76 Lakhs
  • Fermenta Biotech Ltd receives FSSAI nod for its product Vitamin D3 (Cholecalciferol) - Plant Source
  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Concord Biotech Ltd completes ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Concord Biotech Ltd receives ANDA approval from USFDA for Mycophenolate Mofetil for Oral Suspension USP
  • Rossari Biotech Ltd consolidated Q4 FY2026 PAT climbs to Rs. 45.96 crores
  • Rossari Biotech Ltd recommends final dividend of Rs. 0.50
  • Windlas Biotech Announces ₹47 Crore Share Buyback at ₹1,000 per Share
  • Indrayani Biotech Limited Finalizes Terms for ₹49.90 Crore Rights Issue
  • Unitop Chemicals Pvt Ltd commissions 15000 MTPA ethoxylation capacity
  • Modi Biotech Pvt Ltd commissions commercial operations of ethanol plant
  • Indo US Bio-Tech Ltd Q3 FY2025-26 net profit lower at Rs. 2.99 crore
  • Rossari Biotech Ltd Q3FY26 consolidated profit at Rs. 32.77 crores
  • Medicamen Biotech Ltd gets EU approval for Paracetamol from Danish Medicine Authority
  • Vivo Bio Tech Ltd receives GLP compliance from NGCMA
  • Titan Biotech Ltd fixes Feb 20, 2026 as record date for 5:1 stock split
  • Fermenta ranked among India's Best Workplaces™ in Pharmaceuticals, Healthcare & Biotech by Great Place to Work®
  • Fermenta Board approves INR 110 Crore Capex at Dahej for Plant-based Vitamin D3, Green Chemistry Enzyme, and Vitamin D3 Derivatives
  • Coastal Biotech Pvt Ltd receives allocation for Supply of Ethanol to OMC's under Ethanol Blended Petrol Programme
  • Rossari Biotech Ltd Q2 FY2025-26 consolidated PAT increases to Rs. 36.87 crores
  • Concord Biotech Ltd completes NAFDAC inspection successfully
  • Fermenta Biotech Limited Certified as a Great Place to Work®

Latest Post

  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025